Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Journal of Clinical Pharmacology
|
December 5, 2002
No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers
Paul D Martin, John Kemp, Aaron L Dane, et al.
Journal of Clinical Pharmacology
|
October 5, 2002
No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor
Paul D Martin, Aaron L Dane, Olise M Nwose, et al.
British Journal of Clinical Pharmacology
|
March 5, 2004
The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive
Steven G Simonson, Paul D Martin, Mike J Warwick, et al.
Journal of Clinical Pharmacology
|
July 20, 2005
Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics
Steven G Simonson, Paul D Martin, Patrick D Mitchell, et al.
British Journal of Clinical Pharmacology
|
January 22, 2003
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Kelvin J Cooper, Paul D Martin, Aaron L Dane, et al.
Clinical Pharmacology and Therapeutics
|
April 24, 2003
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Kelvin J Cooper, Paul D Martin, Aaron L Dane, et al.
European Journal of Clinical Pharmacology
|
September 22, 2015
Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia
Merran Macpherson, Bengt Hamrén, Marjet J A M Braamskamp, et al.
Clinical Therapeutics
|
December 25, 2003
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers
Paul D Martin, Mike J Warwick, Aaron L Dane, et al.
Current Medical Research and Opinion
|
August 5, 2008
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia
Tsang-Bin Tzeng, Dennis W Schneck, Bruce K Birmingham, et al.
Clinical Therapeutics
|
May 24, 2011
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study
Li Zhang, Su Li, Yang Zhang, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Journal of Clinical Pharmacology
|
December 5, 2002
No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers
Paul D Martin, John Kemp, Aaron L Dane, et al.
Journal of Clinical Pharmacology
|
October 5, 2002
No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor
Paul D Martin, Aaron L Dane, Olise M Nwose, et al.
British Journal of Clinical Pharmacology
|
March 5, 2004
The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive
Steven G Simonson, Paul D Martin, Mike J Warwick, et al.
Journal of Clinical Pharmacology
|
July 20, 2005
Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics
Steven G Simonson, Paul D Martin, Patrick D Mitchell, et al.
British Journal of Clinical Pharmacology
|
January 22, 2003
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Kelvin J Cooper, Paul D Martin, Aaron L Dane, et al.
Clinical Pharmacology and Therapeutics
|
April 24, 2003
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Kelvin J Cooper, Paul D Martin, Aaron L Dane, et al.
European Journal of Clinical Pharmacology
|
September 22, 2015
Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia
Merran Macpherson, Bengt Hamrén, Marjet J A M Braamskamp, et al.
Clinical Therapeutics
|
December 25, 2003
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers
Paul D Martin, Mike J Warwick, Aaron L Dane, et al.
Current Medical Research and Opinion
|
August 5, 2008
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia
Tsang-Bin Tzeng, Dennis W Schneck, Bruce K Birmingham, et al.
Clinical Therapeutics
|
May 24, 2011
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study
Li Zhang, Su Li, Yang Zhang, et al.
Page
of 3